Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Concept/Terms
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 7 | 8 | 15 |
| 1997 | 11 | 7 | 18 |
| 1998 | 10 | 9 | 19 |
| 1999 | 8 | 7 | 15 |
| 2000 | 17 | 3 | 20 |
| 2001 | 11 | 8 | 19 |
| 2002 | 13 | 7 | 20 |
| 2003 | 22 | 12 | 34 |
| 2004 | 22 | 6 | 28 |
| 2005 | 18 | 19 | 37 |
| 2006 | 30 | 16 | 46 |
| 2007 | 17 | 19 | 36 |
| 2008 | 32 | 21 | 53 |
| 2009 | 26 | 13 | 39 |
| 2010 | 17 | 9 | 26 |
| 2011 | 30 | 23 | 53 |
| 2012 | 31 | 8 | 39 |
| 2013 | 34 | 19 | 53 |
| 2014 | 27 | 21 | 48 |
| 2015 | 44 | 13 | 57 |
| 2016 | 22 | 9 | 31 |
| 2017 | 25 | 13 | 38 |
| 2018 | 14 | 16 | 30 |
| 2019 | 20 | 13 | 33 |
| 2020 | 16 | 11 | 27 |
| 2021 | 19 | 5 | 24 |
| 2022 | 3 | 9 | 12 |
| 2023 | 0 | 7 | 7 |
| 2024 | 0 | 3 | 3 |
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024 Mar 21; 390(12):1080-1091.
-
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. Clin Cancer Res. 2024 Mar 15; 30(6):1093-1103.
-
Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial. Breast Cancer Res Treat. 2024 Apr; 204(3):547-559.
-
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol. 2023 Dec; 84(6):579-587.
-
Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2024 Jan 01; 118(1):94-103.
-
Precision medicine in extended adjuvant endocrine therapy for breast cancer. Curr Opin Oncol. 2023 11 01; 35(6):453-460.
-
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. Oncologist. 2023 07 05; 28(7):596-603.
-
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer. Curr Treat Options Oncol. 2023 06; 24(6):594-610.
-
Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS One. 2023; 18(2):e0281508.
-
Defining Patient Benefits from High-intensity Intermittent Therapy for Hormone-sensitive Prostate Cancer. Eur Urol Focus. 2023 05; 9(3):419-421.